Silexion Therapeutics Corp (SLXN): Nasdaq/NYSE listing notice — Silexion Therapeutics receives Nasdaq delisting notice; plans appeal

Silexion Therapeutics Corp

Received delisting notice on May 22, 2025 for MVLS <$50M and MVPHS <$15M non-compliance.
Failed to regain compliance within 180-day period ending May 19, 2025.
Intends to appeal by May 29, 2025; trading suspension effective June 2, 2025 if appeal fails.
Plans to request transfer to Nasdaq Capital Market; requires at least $2.5M shareholders' equity.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(C)

Exact text from the filing

”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-25-001941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.